Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).

Jan Van Droogenbroeck,Noa Lavi,Jiayu Fu,Ka Lung Wu,Wendy Crist,Huaibao Feng,Yael Cohen,Jordan Schecter,Philip Vlummens,Robin L Carson

doi:10.1200/jco.2018.36.15_suppl.tps8057

Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).

Jan Van Droogenbroeck, Noa Lavi + Show 8 more

https://doi.org/10.1200/jco.2018.36.15_suppl.tps8057

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 1

Affiliation: AZ Sint-Jan, Rambam Health Care Campus, Janssen (United States), Ziekenhuisnetwerk Antwerpen Stuivenberg, Tel Aviv University, Ghent University, Ghent University Hospital

#Relapsed/refractory Multiple Myeloma #Daratumumab #Human CD38 Monoclonal Antibody #Study Of Daratumumab #Multiple Myeloma #Monoclonal Antibody #Human Monoclonal Antibody #Deep Responses #Treatment Of Relapsed/refractory Multiple Myeloma #Deep Clinical Responses

Abstract
Full-Text
Similar Papers

Abstract

Listen

TPS8057Background: DARA, a human CD38 monoclonal antibody, is approved for treatment of RRMM. DARA produces deep clinical responses in RRMM and induces T-cell expansion through reduction of immune ...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).